Last update June 10, 2018

Inosine Dimepranol Acedoben

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

A nucleoside derivative with antiviral properties. There is little published data on this product and little evidence of its efficacy as an antiviral (You 2015, Kinghorn 1992, Mindel 1989, Pachuta 1974) and even less as an immunostimulant (Smith 2015, Trentham 199).
It has been used with poor results in infections due to herpes simplex, genital warts, colds, subacute sclerosing panencephalitis, chronic fatigue syndrome and rheumatoid arthritis.
Administered orally every 4 to 6 hours for 2 to 4 weeks.

Since the last update we have not found published data on its excretion in breastmilk.

The little known pharmacokinetic data (high molecular weight and short half-life) make transfer to milk in significant amounts unlikely.

The manufacturer indicates its use in children, even from the first month of life. Possible side effects are usually mild and infrequent.

As there is less published information than for other drugs from the same group, safer known alternatives may be preferable during the neonatal period and in case of prematurity.


Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Inosine Dimepranol Acedoben is also known as

Inosine Dimepranol Acedoben in other languages or writings:


Inosine Dimepranol Acedoben belongs to this group or family:


Main tradenames from several countries containing Inosine Dimepranol Acedoben in its composition:


Variable Value Unit
Oral Bioavail. 90 %
Molecular weight 1115 daltons
Tmax 1 hours
0.9 hours


  1. You Y, Wang L, Li Y, Wang Q, Cao S, Tu Y, Li S, Bai L, Lu J, Wei Z, Chen W, Hao F. Multicenter randomized study of inosine pranobex versus acyclovir in the treatment of recurrent herpes labialis and recurrent herpes genitalis in Chinese patients. J Dermatol. 2015 Abstract
  2. Smith ME, Haney E, McDonagh M, Pappas M, Daeges M, Wasson N, Fu R, Nelson HD. Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015 Abstract
  3. Aventis. Isoprinosine Ficha técnica. 2014 Full text (in our servers)
  4. IMB. Isoprinosine. Drug Summary. 2014 Full text (in our servers)
  5. Kinghorn GR, Woolley PD, Thin RN, De Maubeuge J, Foidart JM, Engst R. Acyclovir vs isoprinosine (immunovir) for suppression of recurrent genital herpes simplex infection. Genitourin Med. 1992 Abstract
  6. Trentham DE. Immunotherapy and other novel therapies. Curr Opin Rheumatol. 1991 Abstract
  7. Mindel A, Carney O, Sonnex C, Freris M, Patou G, Williams P. Suppression of frequently recurring genital herpes: acyclovir v inosine pranobex. Genitourin Med. 1989 Abstract
  8. Pachuta DM, Togo Y, Hornick RB, Schwartz AR, Tominaga S. Evaluation of isoprinosine in experimental human rhinovirus infection. Antimicrob Agents Chemother. 1974 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM